JPWO2020018922A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018922A5 JPWO2020018922A5 JP2021502833A JP2021502833A JPWO2020018922A5 JP WO2020018922 A5 JPWO2020018922 A5 JP WO2020018922A5 JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021502833 A JP2021502833 A JP 2021502833A JP WO2020018922 A5 JPWO2020018922 A5 JP WO2020018922A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- antibody
- sequence
- disease
- single antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 3
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 3
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000037914 B-cell disorder Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020312A JP2024073430A (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701281P | 2018-07-20 | 2018-07-20 | |
| US62/701,281 | 2018-07-20 | ||
| PCT/US2019/042633 WO2020018922A1 (en) | 2018-07-20 | 2019-07-19 | Heavy chain antibodies binding to cd19 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020312A Division JP2024073430A (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530236A JP2021530236A (ja) | 2021-11-11 |
| JPWO2020018922A5 true JPWO2020018922A5 (zh) | 2022-07-26 |
| JP7439046B2 JP7439046B2 (ja) | 2024-02-27 |
Family
ID=67515196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502833A Active JP7439046B2 (ja) | 2018-07-20 | 2019-07-19 | Ｃｄ１９に結合する重鎖抗体 |
| JP2024020312A Pending JP2024073430A (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020312A Pending JP2024073430A (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210332133A1 (zh) |
| EP (1) | EP3823990A1 (zh) |
| JP (2) | JP7439046B2 (zh) |
| KR (1) | KR20210032311A (zh) |
| CN (2) | CN116769032A (zh) |
| AU (1) | AU2019305663A1 (zh) |
| BR (1) | BR112020024074A2 (zh) |
| CA (1) | CA3101069A1 (zh) |
| IL (1) | IL279010A (zh) |
| MX (1) | MX2021000708A (zh) |
| SG (1) | SG11202011597RA (zh) |
| WO (1) | WO2020018922A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
| JP7030109B2 (ja) | 2016-09-14 | 2022-03-04 | テネオバイオ， インコーポレイテッド | Ｃｄ３結合抗体 |
| EP3642237A2 (en) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
| KR20200104342A (ko) | 2017-12-22 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd22에 결합하는 중쇄 항체 |
| AR119746A1 (es) | 2019-06-14 | 2022-01-05 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| BR112022021690A2 (pt) | 2020-04-29 | 2022-12-20 | Teneobio Inc | Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas |
| WO2021222578A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| KR20230038706A (ko) * | 2020-07-16 | 2023-03-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Cd19 결합 분자 및 이의 용도 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| CA3214283A1 (en) * | 2021-04-06 | 2022-10-13 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| DK1853718T3 (en) * | 2005-02-15 | 2015-11-09 | Univ Duke | ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| HUE025778T2 (en) * | 2008-07-17 | 2016-05-30 | Novartis Ag | Preparations and methods for the use of therapeutic antibodies |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TWI706960B (zh) * | 2014-09-26 | 2020-10-11 | 美商宏觀基因股份有限公司 | 能夠結合cd19和cd3的雙特異性雙抗體及其用途 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
| KR20190052006A (ko) | 2016-08-24 | 2019-05-15 | 테네오바이오, 인코포레이티드 | 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물 |
| JP7030109B2 (ja) | 2016-09-14 | 2022-03-04 | テネオバイオ， インコーポレイテッド | Ｃｄ３結合抗体 |
-
2019
- 2019-07-19 JP JP2021502833A patent/JP7439046B2/ja active Active
- 2019-07-19 CN CN202310539593.8A patent/CN116769032A/zh active Pending
- 2019-07-19 EP EP19749123.6A patent/EP3823990A1/en active Pending
- 2019-07-19 AU AU2019305663A patent/AU2019305663A1/en active Pending
- 2019-07-19 KR KR1020207034987A patent/KR20210032311A/ko unknown
- 2019-07-19 US US17/260,213 patent/US20210332133A1/en active Pending
- 2019-07-19 CA CA3101069A patent/CA3101069A1/en active Pending
- 2019-07-19 SG SG11202011597RA patent/SG11202011597RA/en unknown
- 2019-07-19 CN CN201980035712.8A patent/CN112351997B/zh active Active
- 2019-07-19 MX MX2021000708A patent/MX2021000708A/es unknown
- 2019-07-19 BR BR112020024074-5A patent/BR112020024074A2/pt unknown
- 2019-07-19 WO PCT/US2019/042633 patent/WO2020018922A1/en active Application Filing
-
2020
- 2020-11-26 IL IL279010A patent/IL279010A/en unknown
-
2024
- 2024-02-14 JP JP2024020312A patent/JP2024073430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014228962B2 (en) | Multimerization technologies | |
| JP3803790B2 (ja) | 新規なダイアボディ型二重特異性抗体 | |
| CN103221427B (zh) | 抗ox40抗体和使用其的方法 | |
| JP2020537644A5 (zh) | ||
| EP3166973B1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| EP3645742A2 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| JP2020525032A5 (zh) | ||
| JP2022169504A5 (zh) | ||
| RU2004121673A (ru) | Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей | |
| JPWO2020018922A5 (zh) | ||
| JP2022516301A (ja) | Ｃｄ１３７アゴニスト性抗体とその使用 | |
| CN104829716A (zh) | 用于治疗疾病的抗人sema4A抗体 | |
| JPH08501925A (ja) | 糖蛋白ｐに対するモノクローナル抗体 | |
| JP2852705B2 (ja) | 自己免疫疾患の治療 | |
| JPWO2020206330A5 (zh) | ||
| JP2024012258A (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| JP2005333993A (ja) | 新規なダイアボディ型二重特異性抗体 | |
| WO2023045370A1 (zh) | 靶向tigit的单克隆抗体 | |
| JPWO2020059847A5 (zh) | ||
| JPWO2020252366A5 (zh) | ||
| JPWO2020087065A5 (zh) | ||
| JPWO2021222578A5 (zh) | ||
| US20030180799A1 (en) | Antibodies against plasma cells | |
| CA3130348A1 (en) | A method for immunosuppression | |
| JP2020509745A5 (zh) |